Cognitively healthy older adults with very high blood levels of phosphorylated tau 217 faced a 38 percent absolute risk of developing cognitive impairment within five years, according to a new international study led by researchers at the Mass General Brigham Neuroscience Institute. The findings were presented at the Alzheimer's Association International Conference and published simultaneously in JAMA. The question matters now because a p-tau217 blood test recently received federal clearance, raising the practical issue of what such a result actually tells someone who has no symptoms.
The team pooled data from six observational and clinical trial studies across North America, Japan, and Australia, covering 2,684 cognitively unimpaired older adults. Participants gave blood samples and underwent PET imaging at enrollment, then returned for annual cognitive assessments. Enrollment in the earliest study began in 2004, with follow-up continuing through 2025. About 478 participants went on to develop cognitive impairment, and higher baseline p-tau217 levels were significantly associated with that outcome. At 10 years, the estimated risk for those with very high levels rose to 78 percent - though the researchers note the data supporting the longer-term figures were considerably sparser.
The investigators are explicit that these numbers do not yet translate into a reason for asymptomatic people to be tested. There are no disease-modifying treatments available for someone who learns they are at elevated risk but has no symptoms, and the researchers say their medical advice would be identical either way: regular exercise, a healthy diet, good sleep, and attention to overall wellness. That is the core limitation of prediction without intervention.
What could change the calculus are the disease-modifying therapy trials currently underway. If those prove beneficial, a blood test like this one could help identify the people most likely to gain from early treatment. The researchers describe their long-term ambition in familiar terms - reaching the point where a p-tau217 result informs Alzheimer's risk the way a cholesterol reading informs heart attack risk.